Gracell Biotechnologies

Congratulations!" Wonderful to see the positive impact of science through AstraZeneca's achievements. Kudos to all involved!"

I am thrilled to share the exciting news that Gracell Biotechnologies was nominated as one of the Annual Top 50 Most Innovative Enterprises in the Biopharma Industry in China, and has received the prestigious Pharma BIG Star award!   This is a tremendous achievement and a testament to the efforts, dedication, and innovation of Gracell’s entire team.   The cell therapy pioneers joined the AstraZeneca organization earlier this year and it’s a privilege to be working with such a talented and passionate team as we continue to push the boundaries of science.

Let's work together to constantly push the boundaries of science, pioneer the innovation of cell therapies and deliver life-changing medicines for patients in need. 🤟

#EarthDay As a member of AstraZeneca Group, Gracell Biotechnologies is committed to contributing to a more sustainable future for people, society and the planet. We recognise that adopting circular business approaches and implementing efficient processes to develop and produce our medicines are key to delivering medicines that improve patient outcomes and minimise the burden on the planet. We fully support AstraZeneca’s approach to the circular economy:  • To minimise the amount of materials required and waste generated during manufacture and use of our products • Maximise proportion of waste recycled and aim to eliminate waste to landfill. • Increase reused or recycled content of the materials we use (both directly, and in our supply chain) Find out more about environmental sustainability at AstraZeneca: https://lnkd.in/dW4PBuJr

Today marks a monumental chapter in our journey - we're thrilled to announce that Gracell has entered into a definitive agreement to be acquired by AstraZeneca. This is a testament to our team's relentless dedication and innovative spirit. A heartfelt thank you to our incredible team and supportive partners. Your trust has been integral to our success. Here's to a future filled with growth, innovation, and continued excellence! Find our more here: https://lnkd.in/eUW_m6QV #celltherapy #grcl

We are thrilled to announce that our company has received clearance from China's NMPA for our IND application to commence the Phase 1/2 clinical trial of FasTCAR-T GC012F for treating Refractory Systemic Lupus Erythematosus (rSLE). GC012F represents a significant advancement in our commitment to innovative therapeutic solutions. We believe this product has the extensive potential and we seek to offer a more effective and long-lasting treatment option for SLE patients, particularly for those grappling with severe and complex forms of the disease. Stay tuned for more updates as we embark on this exciting journey towards transforming the lives of those affected by lupus! Find out more here: https://lnkd.in/e3piu5WE #celltherapy #GRCL

On what sets Gracell and FasTCAR-T GC012F apart, our CEO, Dr. William Cao, discusses the latest clinical data of GC012F in the front line multiple myeloma treatment setting in an interview with BiotechTV. Watch here: https://lnkd.in/gt8BJBex #GRCL #celltherapy

We look forward to presenting the latest findings on FasTCAR-T GC012F at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. With more patients and extended follow-up, GC012F shows remarkable responses and safety in treating newly-diagnosed multiple myeloma in this ongoing investigator-initiated study. We believe GC012F could become a game-changer CAR-T therapy! Find more details here: https://lnkd.in/grVrATPB #ASH2023 #GRCL #celltherapy